ACTRN12615000857505已完成1 期
A randomized, double-blind, placebo-controlled, cross-over study to evaluate the prebiotic effect of Manuka Honey with Cyclopower (Trademark) capsules in healthy subjects.
The New Zealand Institute for Plant and Food Research0 个研究点目标入组 20 人开始时间: 2015年8月18日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 45 Years(—)
- 性别
- All
入选标准
- •1. Healthy subjects age 18 to 45 years of age inclusive, and in good health as determined by past medical history, physical examination, vital signs at screening.
- •2. Subjects must be non-smoking (no use of tobacco products in the previous 3 months).
- •3. Subjects must have a body mass index (BMI) within the range of 18 to 29 kg/m2 inclusive at screening.
- •4. Subjects of childbearing potential must be using an acceptable method of contraception for the duration of the study.
- •5. Subjects must be able to communicate well with the investigator, to
- •understand and comply with the requirements of the study and
- •understand and sign the written informed consent.
- •6.Subjects must be willing not to use any other probiotic or prebiotic supplements for the duration of this study. Note: The eating of yoghurt / probiotic foods may continue during the study as long as there is no change in the product eaten or in the amount and frequency of ingestion.
排除标准
- •1.A past medical history of clinically significant disease or abnormality.
- •2.Known allergy to any bee products or Honey Cyclopower
- •3.Known allergies or food intolerance to fibre-based products
- •4.Use of any prescription drugs within 7 days prior to initial dosing in this study, other than occasional use of analgesics (less than 3 days in any 7-day period) and hormonal contraceptives
- •5.Use of any recreational drugs in last 7 days prior to initial dosing in this study
- •6.Significant illness within two (2) weeks prior to initial dosing.
- •7.Dosing of a study drug in any clinical investigation within 30 days prior to initial dosing in this study.
- •8.Pregnant and breast feeding women.
研究者
相似试验
已完成
不适用
A randomized, double-blind, placebo-controlled, crossover study on the suppressive effect of the peptide on postprandial blood glucose levelot applicableJPRN-UMIN000048002CPCC Company Limited30
进行中(未招募)
不适用
A study assessing the safety, tolerability and efficacy of a new medication (SER100) in patients with Isolated Systolic Hypertension (ISH) insufficiently treated with 1-3 other anti-hypertensives.MedDRA version: 14.1Level: LLTClassification code 10050591Term: Isolated systolic hypertensionSystem Organ Class: 100000004866Isolated Systolic HypertensionEUCTR2013-001227-40-HUSerodus ASA30
已完成
Unknown
A clinical trial assessing the efficacy and safety of DA-5521 in treating hangoversKCT0008927Dong-A Pharm24
已完成
2 期
A randomized, double-blind, placebo-controlled, cross-over study to assess the effects of fampridine on eye movements and nerve conduction and function in patients with multiple sclerosis (MS) and a unilateral or bilateral internuclear ophthalmoplegia (INO)nerve disease10012303multiple sclerosisNL-OMON42310Centre for Human Drug Research24
进行中(未招募)
1 期
Multi-center trial in healthy subjects to investigate the effects of analgesic drugs on pain processing observed by Peripheral Nerve Excitability Testing (NET)Healthy volunteers (intended indication: pain)MedDRA version: 20.0Level: PTClassification code 10033371Term: PainSystem Organ Class: 10018065 - General disorders and administration site conditionsEUCTR2019-000942-36-ITMBERTO I - POLICLINICO DI ROMA60
